Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 12, 2018-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its fourth quarter and full-year 2017 financial results after the close of market on Tuesday, February 27, 2018 . Following the announcement, Veracyte will host a
View HTML
Toggle Summary Veracyte to Present at LEERINK Partners 7th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 31, 2018-- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the LEERINK Partners 7 th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 2:00 p.m.
View HTML
Toggle Summary Veracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
Milestone Comes During National Thyroid Awareness Month SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 25, 2018-- During National Thyroid Awareness Month in January, Veracyte, Inc. (NASDAQ: VCYT) announced that to date it has performed 100,000 Afirma genomic tests to help reduce unnecessary
View HTML
Toggle Summary Veracyte's Chief Science and Medical Officer to Present at The Precision Medicine World Conference
Dr. Giulia Kennedy will highlight company's successful use of machine learning to develop genomic diagnostic tests SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that Giulia C. Kennedy , Ph.D., chief science and medical officer, will present at the Precision
View HTML
Toggle Summary Veracyte Announces Publication of Results from Patient Survey Quantifying the Challenges in Diagnosing Interstitial Lung Disease
55% of participants in national Pulmonary Fibrosis Foundation survey reported at least one misdiagnosis; 61% endured an invasive procedure for diagnosis Authors call for improved physician education, practical clinical guidelines and better diagnostic tools SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Veracyte Announces Strategic Realignment and New Appointments to Advance Commercial Growth
Company Reiterates 2017 Revenue and Cash Burn Guidance SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced key business initiatives, including strategic realignments to its corporate structure and new appointments, to advance commercial growth of its three
View HTML
Toggle Summary Veracyte Announces Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that data confirming the analytical validity of the company's Envisia™ Genomic Classifier have been published online in the journal BMC Pulmonary Medicine . The findings add to the growing body of evidence,
View HTML
Toggle Summary Veracyte to Present at the Piper Jaffray 29th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Piper Jaffray 29 th Annual Healthcare Conference on Tuesday, November 28, 2017 at 9:30 a.m.
View HTML
Toggle Summary Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology
- Interim CATALYST Study Findings Presented at PFF Summit - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that new data for the Envisia™ Genomic Classifier were presented today and demonstrate that the test - in real-world clinical scenarios - can enable
View HTML
Toggle Summary Veracyte Announces Third Quarter 2017 Financial Results
Reports Revenue of $17.5 Million for the Third Quarter 2017 Highlights Business Progress Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the third quarter ended September 30, 2017
View HTML